We have 3 of 69 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Biofluid biomarkers
INTRODUCTION Alzheimer's disease (AD) is the most common neurodegenerative dementia affecting millions globally. Therapies primarily consist of symptomatic management and progression limitation. Further advances in treatments include disease-modifying therapies, many of which have unfavorable safety profiles and modest...
Targeting autophagy offers a promising and potentially safe avenue for slowing AD progression and should prioritize the development of selective autophagy modulators and personalized treatment strategies to restore autophagic flux and enhance clinical outcomes in patients with AD.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
